Diagnostics company bioMerieux (PARIS:BIM) has received 510(k) clearance from the U.S. Food and Drug Administration for a test to detect and screen for methicillin-resistant staphylococcus, more commonly called MRSA. BioMerieux said that its automated molecular test, called NucliSENS EasyQ MRSA, detects seven MRSA types and covers the most prevalent strains. The advantage of molecular-based testing […]
Diagnostics company bioMerieux (PARIS:BIM) is acquiring French microbiological analysis company AES Laboratoire for $260 million. France-based bioMerieux, which has its U.S. headquarters in Durham, North Carolina, gains AES’ expertise in analyzing microbiological samples in industrial settings. The acquisition is bioMerieux’s ninth in five years. BioMerieux’s strength is in medical diagnostics and some of the company’s […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
New personalized medicine cancer tests will be developed through a partnership announced between bioMerieux and Ipsen. Besides diagnosing disease, the companies expect the tests will also help speed development of new drugs to treat various cancers.